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Gynecological cancer
Results of curative treatment in cervical carcinoma
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We analyze the characteristics and results of the treatment of 206 patients with a diagnosis of carcinoma of cervix treated
between 2006 and 2012 with curative radiotherapy.
General characteristics. Median age: 54 years (23–90). Histology: squamous cell carcinoma 158 (77%), adenosquamous 34 (17%).
Stages. Stage Ib and II 169 patients, III 24 and IV 8 patients. Only 53 patients have nodal involvement (26%). Concomitant
chemotherapy to external radiotherapy was administrated to 132 patients (64%), utero-vaginal brachytherapy was associated
to external radiation in 190 cases (92%). Previously to brachytherapy, clinical response of external radiation and chemotherapy
was assessed. Total response was in 33% of the cases, partial response >75% in 47% of the cases and partial response >50% was
13%.
Results. With a median follow up of 33 months (6–123), 185 patients (90%) obtained local control of the disease. Nodal recurrence
is evidenced in 9 (4%) and metastases in 23 (11%) The most common location is in the lungs (8/23). -Loco-regional relapse-free
survival is 84% at 2 years and 81% at 5 and 10 years. -The nodal relapse-free survival is 85% at 2 years and 80% at 5 and 10 years.
-Metastasis-free survival is 82% at 2 years and 78% at 5 and 10 years. -The disease-free survival at 2 years is 82% and at 5 and 10
years of 81%. -Overall survival at 2 years is 88% and at 5 and 10 years 83%. No evidence of signiﬁcant urinary or gastrointestinal
toxicity in both acute and late effects was observed.
Conclusion. The association of chemotherapy to external radiotherapy and uterovaginal brachytherapy has evidenced to be an
effective treatment for patients with cervical carcinoma.
http://dx.doi.org/10.1016/j.rpor.2013.03.225
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Introduction. Adenosarcomas of the uterus (ADS) are relatively rare uterine sarcomas, with a very low incidence; nowadays there
is little information about ADS behaviour, histological features, prognosis factors and treatment. We retrospectively analysed
the outcome of 12 patients diagnosed and treated at our centre.
Material and methods. From 1979 to 2012 the records and pathology of 12 patients diagnosed with ADS and treated at our centre
were reviewed. Total abdominal hysterectomy and bilateral salpingo-oophorectomy was considered as the standard surgical
procedure for all the patients and only four lymphadenectomy were made. External beam radiotherapy (EBRT) was administered
in three patients as adjuvant therapy and four patients received brachytherapy. The Kaplan- Meier actuarial method was used
to analyse the overall survival (OS) and disease-free survival (DFS).
Results. The median follow up of the patients was 50 months and it ranged between 3 and 190 months. After surgery all the
12 patients had limited uterus disease. Five patients had a relapse (41%), two cases were limited to the pelvis, in two patients
metastatic disease was associated to local relapse and one case of exclusively metastases. The irradiated patients mean DFS
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was 47.8 months; instead, the non-adjuvant patients mean DFS was 25 months. No differences on OS were seen. Four of twelve
(33%) patients are still alive.
Conclusions. Eventhough uterus limited ADS (stage I) have a relatively favourable clinical outcome, comparing with others uterine
sarcomas, the present study suggested that surgery (including pelvic and paraortic lymphadenectomy) and radiotherapy (EBRT
and/or BQT) confer a lower local failure rate than surgery alone in either ADS stage I. Optimal therapy is still unclear and this
series provides knowledge about adjuvant therapy and prognosis in ADS stage I.
http://dx.doi.org/10.1016/j.rpor.2013.03.226
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Introduction/Purpose. Metastases from endometrial carcinoma in central nervous system (CNS) are an uncommon site with
extremely poor prognosis. Low incidence is observed (0.3–0.9% among all endometrial carcinomas) and median time from pri-
mary diagnosis tometastases diagnosis is about 11months. Risk factors are tumoral grade (undifferentiated),miometrial invasion
depth (>50%), linfovascular invasion (LVI) and endometrioid carcinomahistology. Sintomatology consists of neurological disturbs,
such as convulsions, headache disorientation, aphasia and memory disturbs. We present a case and literature review has been
made.
Material and methods. A 76 years old woman was diagnosed from endometrial adenocarcinoma stage Ib, G3 and LVI+, after starting
with metrorragic symptoms. 2 months after primary diagnosis she presented neurological disturbs consisting in aphasia. CT
and MRI were performed and showed a single left parietal lesion, that was conﬁrmed to be a brain metastase from endometrial
adenocarcinomaby biopsy. Surgerywith complete exeresis of this lesionwas performed, and surgical intervention for the primary
tumor was made 2 months later.
Results. 2 months after brain lesion resection, hysterectomy was performed. Starting holocraneal radiotherapy as adjuvant treat-
ment, the patient presented a new convulsive crisis. Brain MRI showed a new lesion where the previous one was. The patient
entered into an epileptic non-convulsive status and died 10 days later.
Conclusions. Overall survival after brain metastases development in patients with endometrial carcinoma is poor. Combination
treatment with surgery and radiation therapy may improve survival for selected patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.227
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Objective. To evaluate if radiotherapy planning with 18F-FDG PET/CT in cervical cancer (CC) can modify the gross tumor volume
(GTV) to be irradiated compared to MRI and additional diagnostic paraortic limphadenectomy. In addition, if PET/CT provides
additional information on initial staging of CC.
Materials and methods. We retrospectively analysed 12 patients with CC, who had a PET/CT scan performed for radiotherapy
planning and an MRI with an interval of time not exceeding 30 days. The GTV determined by PET/CT measure also included
subcentimetric lymph nodes with pathological 18F-FDG uptake (SUVmax>2.5).
Results. In 8/12 patients PET/CT did not induce changes in the delimitation of primary tumor and/or local spread. In 3/12 PET/CT
underestimated the GTV (MRI showed millimetric lymphadenopaties in pelvic lymph nodes suggestive of malignancy in 2
patients, while PET/CT did not reveal pathological uptake of 18F-FDG in this location, probably due to the small size of these
lymph nodes). In 2/12 PET/CT modiﬁed the nodal GTV. The PET/CT revealed pathological uptake of 18F-FDG in pelvic lymph
nodes whereas MRI did not. The PET/CT did not revealed pathological uptake of 18F-FDG in retroperitoneal lymph nodes (none
patients). In 10/12 patients diagnostic paraortic limphadenectomy was performed after the PET/TC study. The median lymph
nodes were 14.5. Only in one (1/10) it was detected positive pathologic retroperitoneal lymph node. In none patients (0%) PET/CT
detected metastases so the radio-chemotherapy treatment was no modiﬁed.
Conclusion. The combination of the information supplied by MRI and PET/TC and diagnostic paraortic limphadenectomy is useful
in the precise deﬁnition of GTV in CC., minimizing normal tissues radiation. Unknown metastases detected in PET/TC could
modify patient management in these cases.
http://dx.doi.org/10.1016/j.rpor.2013.03.228
